{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:24:26Z","timestamp":1790540666838,"version":"4.1.0"},"reference-count":29,"publisher":"European Respiratory Society (ERS)","issue":"6","funder":[{"DOI":"10.13039\/100009041","name":"National Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2018,10,8]]},"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:p>South African patients with rifampicin-resistant tuberculosis (TB) and resistance to fluoroquinolones and\/or injectable drugs (extensively drug-resistant (XDR) and preXDR-TB) were granted access to bedaquiline through a clinical access programme with strict inclusion and exclusion criteria.<\/jats:p><jats:p>PreXDR-TB and XDR-TB patients were treated with 24\u2005weeks of bedaquiline within an optimised, individualised background regimen that could include levofloxacin, linezolid and clofazimine as needed. 200 patients were enrolled: 87 (43.9%) had XDR-TB, 99 (49.3%) were female and the median age was 34\u2005years (interquartile range (IQR) 27\u201342). 134 (67.0%) were living with HIV; the median CD4<jats:sup>+<\/jats:sup>count was 281 cells\u00b7\u03bcL<jats:sup>\u22121<\/jats:sup>(IQR 130\u2013467) and all were on antiretroviral therapy.<\/jats:p><jats:p>16 out of 200 patients (8.0%) did not complete 6\u2005months of bedaquiline: eight were lost to follow-up, six died, one stopped owing to side effects and one was diagnosed with drug-sensitive TB. 146 out of 200 patients (73.0%) had favourable outcomes: 139 (69.5%) were cured and seven (3.5%) completed treatment. 25\u00a0patients (12.5%) died, 20 (10.0%) were lost from treatment and nine (4.5%) had treatment failure. 22 adverse events were attributed to bedaquiline, including a QT interval corrected using the Fridericia formula (QTcF) &gt;500\u2005ms (n=5), QTcF increase &gt;50\u2005ms from baseline (n=11) and paroxysmal atrial flutter (n=1).<\/jats:p><jats:p>Bedaquiline added to an optimised background regimen was associated with a high rate of successful treatment outcomes for this preXDR-TB and XDR-TB cohort.<\/jats:p>","DOI":"10.1183\/13993003.01528-2018","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T17:06:49Z","timestamp":1540487209000},"page":"1801528","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":117,"title":["High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen"],"prefix":"10.1183","volume":"52","author":[{"given":"Norbert","family":"Ndjeka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Schnippel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqbal","family":"Master","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Meintjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Maartens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Padanilam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Enwerem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunitha","family":"Chotoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalini","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5349-9509","authenticated-orcid":false,"given":"Jennifer","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebrahim","family":"Variava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannetjie","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"te Riele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazir","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nonkqubela","family":"Bantubani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Conradie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2018,10,25]]},"reference":[{"key":"2024102100400613000_52.6.1801528.1","unstructured":"World Health Organization. Global Tuberculosis Report . Geneva, World Health Organization, 2017."},{"key":"2024102100400613000_52.6.1801528.2","unstructured":"South African Department of Health. Electronic Drug Resistant TB Case Register. https:\/\/edrweb.net"},{"key":"2024102100400613000_52.6.1801528.3","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB Treatment-2017","year":"2018","journal-title":"Lancet"},{"key":"2024102100400613000_52.6.1801528.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808427"},{"key":"2024102100400613000_52.6.1801528.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1314385"},{"key":"2024102100400613000_52.6.1801528.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313865"},{"key":"2024102100400613000_52.6.1801528.7","unstructured":"World Health Organization. The Use of Bedaquiline in the Treatment of Multi-Drug Resistant Tuberculosis: Interim Policy Guidance . Geneva, World Health Organization, 2013; p.\u00a064."},{"key":"2024102100400613000_52.6.1801528.8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.7196\/SAMJ.7263","article-title":"Clinical Access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis","volume":"104","author":"Conradie","year":"2014","journal-title":"South African Med J"},{"key":"2024102100400613000_52.6.1801528.9","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0944"},{"key":"2024102100400613000_52.6.1801528.10","unstructured":"World Health Organization. Report of the Guideline Development Group Meeting on the Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis, a Review of Available Evidence . Geneva, World Health Organization, 2017."},{"key":"2024102100400613000_52.6.1801528.11","unstructured":"South African National Department of Health. The South African Antiretroviral Treatment Guidelines . Pretoria, Department of Health, 2013."},{"key":"2024102100400613000_52.6.1801528.12","unstructured":"Sirturo [prescribing information]. Titusville, NJ, Janssen Therapeutics, 2012; p.\u00a025."},{"key":"2024102100400613000_52.6.1801528.13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00191-13"},{"key":"2024102100400613000_52.6.1801528.14","unstructured":"Directorate Drug-Resistant TB, TB & HIV. Management of Drug-Resistant TB: Policy Guidelines . Pretoria, National Department of Health, 2013."},{"key":"2024102100400613000_52.6.1801528.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00009-2"},{"key":"2024102100400613000_52.6.1801528.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2024102100400613000_52.6.1801528.17","unstructured":"Directorate Drug-Resistant TB, TB & HIV. Introduction of new drugs, drug regimens and management for drug-resistant TB in South Africa: policy framework. 1.1. Pretoria, National Department of Health, 2015."},{"key":"2024102100400613000_52.6.1801528.18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","article-title":"Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study","volume":"6","author":"Schnippel","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2024102100400613000_52.6.1801528.19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01891-2015"},{"key":"2024102100400613000_52.6.1801528.20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00724-2015"},{"key":"2024102100400613000_52.6.1801528.21","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00387-2017"},{"key":"2024102100400613000_52.6.1801528.22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01462-2017"},{"key":"2024102100400613000_52.6.1801528.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00146-2017"},{"key":"2024102100400613000_52.6.1801528.24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01350-2018"},{"key":"2024102100400613000_52.6.1801528.25","unstructured":"World Health Organization. Companion Handbook to the Who Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva, World Health Organization, 2014."},{"key":"2024102100400613000_52.6.1801528.26","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis","volume":"82","author":"Van Deun","year":"2010","journal-title":"Am J Crit Care Med"},{"key":"2024102100400613000_52.6.1801528.27","unstructured":"Conradie F , Diacon AH , Everitt D , et al. 2017. The NIX-TB trial of pretomanid, bedaquiline, and linezolid to treat XDR-TB. www.croiwebcasts.org\/p\/2017croi\/croi33483 Date last accessed: November 14, 2018. Date last updated: February 15, 2017."},{"key":"2024102100400613000_52.6.1801528.28","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06126-11"},{"key":"2024102100400613000_52.6.1801528.29","unstructured":"World Health Organization. Rapid Communication: Key changes to Treatment of Multidrug- and Rifampicin-resistant Tuberculosis. Geneva, World Health Organization, 2018."}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01528-2018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:00:34Z","timestamp":1740380434000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01528-2018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,25]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,12,20]]},"published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1183\/13993003.01528-2018"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01528-2018","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,25]]}}}